secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001746473-24-000143
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q2 net loss $55.9M; cash $438.1M; bexotegrast trials on track
--------------------------------------------------------------------------------

- Net loss $55.9M vs $41.2M prior year; R&D expense up to $45.6M driven by BEACON-IPF trial.
- Cash, equivalents & short-term investments $438.1M as of June 30, 2024.
- Phase 2a PET imaging trial showed reduced total lung collagen and improved FVC in IPF patients on bexotegrast.
- BEACON-IPF Phase 2b enrollment on track for Q1 2025 completion; data anticipated mid-2026.
- Steve Krognes, former Denali Therapeutics CFO, appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000143/0001746473-24-000143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000143/plrx-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001746473-24-000143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer